NEW YORK/LONDON (Reuters) – Drug maker Shire Plc (SHP.L) has made a new acquisition offer for peer Baxalta International Inc (BXLT.N) that is roughly in line with the latter’s valuation expectations, making a deal in the coming weeks likely, people familiar with the matter said. An agreement would successfully end Dublin-based Shire’s five-month pursuit of Bannockburn, Illinois-based Baxalta and create one of the world’s leading specialists in rare diseases. Baxalta’s board rejected an all-stock offer from Shire in August, saying it had significantly undervalued the company.